Mutant tumor protein p53 neoantigen peptides (Mutant TP53 neoantigens)

Mutant tumor protein p53 (TP53) neoantigen peptides are short amino acid sequences derived from the intracellular degradation of mutated p53 proteins, which occur in more than half of all human cancers (Surget et al., 2013, PMID: 24025431). These peptides are transported to the cell surface and presented by Human Leukocyte Antigen (HLA) molecules, making them visible to the immune system as 'non-self' (Hsiue et al., 2021, Science). Unlike wild-type p53, which is a self-antigen and typically subject to immune tolerance, these mutant-specific sequences provide a unique window for therapeutic intervention without damaging healthy cells. Current drug development focuses on T-cell receptor (TCR) engineered T-cells, bispecific antibodies, and personalized mRNA vaccines designed to prime the immune system to recognize these specific epitopes (Malekzadeh et al., 2019, JCI). The high prevalence of 'hotspot' mutations in TP53 makes these neoantigens particularly attractive for broad-spectrum cancer immunotherapies across various solid tumors (Yue et al., 2023, Cell Reports Medicine).

Other names

Mutant p53 peptidesTP53 neoepitopesp53 mutation-derived neoantigensp53-derived tumor-specific antigensmTP53 neoantigens

Induction of a targeted T-cell immune response against cancer cells by recognizing specific mutant p53 peptide fragments presented on Human Leukocyte Antigen (HLA) molecules (Hsiue et al., 2021, Science).